FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048687053> ?p ?o ?g. }

• W3048687053 endingPage "69" @default.
• W3048687053 startingPage "60" @default.
• W3048687053 abstract "BackgroundThe effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood.ObjectiveTo evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry.MethodsNested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in the Psoriasis Longitudinal Assessment and Registry. Cases were matched (1:4) with controls by age, race, sex, and geographic region. Evaluated treatments included methotrexate, ustekinumab, and tumor necrosis factor α inhibitors. Exposure was defined as at least 1 dose of treatment within 3 months before death and was stratified by duration of therapy.ResultsAmong 12,090 patients, 341 deaths occurred, matched to 1364 controls. Biologic treatment within the preceding 3 months was protective against mortality versus no exposure: odds ratio (OR) for exposure of less than 1 year, 0.08 (95% confidence interval [CI], 0.03-0.23); OR for exposure of 1 year or longer, 0.09 (95% CI, 0.06-0.13). Methotrexate was protective against mortality only with exposure for 1 year or longer (OR, 0.08; 95% CI, 0.02-0.28).LimitationsObservational studies are subject to unmeasured confounding.ConclusionsBiologic therapy was associated with reduced mortality risk in patients with moderate to severe psoriasis, regardless of treatment duration; methotrexate reduced risk only with exposure for 1 year or longer. The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood. To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry. Nested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in the Psoriasis Longitudinal Assessment and Registry. Cases were matched (1:4) with controls by age, race, sex, and geographic region. Evaluated treatments included methotrexate, ustekinumab, and tumor necrosis factor α inhibitors. Exposure was defined as at least 1 dose of treatment within 3 months before death and was stratified by duration of therapy. Among 12,090 patients, 341 deaths occurred, matched to 1364 controls. Biologic treatment within the preceding 3 months was protective against mortality versus no exposure: odds ratio (OR) for exposure of less than 1 year, 0.08 (95% confidence interval [CI], 0.03-0.23); OR for exposure of 1 year or longer, 0.09 (95% CI, 0.06-0.13). Methotrexate was protective against mortality only with exposure for 1 year or longer (OR, 0.08; 95% CI, 0.02-0.28). Observational studies are subject to unmeasured confounding. Biologic therapy was associated with reduced mortality risk in patients with moderate to severe psoriasis, regardless of treatment duration; methotrexate reduced risk only with exposure for 1 year or longer." @default.
• W3048687053 created "2020-08-18" @default.
• W3048687053 creator A5013763025 @default.
• W3048687053 creator A5024409404 @default.
• W3048687053 creator A5038975475 @default.
• W3048687053 creator A5039054307 @default.
• W3048687053 creator A5061849637 @default.
• W3048687053 creator A5069686473 @default.
• W3048687053 creator A5069977428 @default.
• W3048687053 date "2021-01-01" @default.
• W3048687053 modified "2023-10-14" @default.
• W3048687053 title "Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis" @default.
• W3048687053 cites W1515251814 @default.
• W3048687053 cites W1775522749 @default.
• W3048687053 cites W1963732230 @default.
• W3048687053 cites W1969097286 @default.
• W3048687053 cites W1975162362 @default.
• W3048687053 cites W2005404141 @default.
• W3048687053 cites W2010277266 @default.
• W3048687053 cites W2046066375 @default.
• W3048687053 cites W2063631155 @default.
• W3048687053 cites W2068419991 @default.
• W3048687053 cites W2073606870 @default.
• W3048687053 cites W2089274189 @default.
• W3048687053 cites W2104684016 @default.
• W3048687053 cites W2118426776 @default.
• W3048687053 cites W2118617167 @default.
• W3048687053 cites W2132923004 @default.
• W3048687053 cites W2146444857 @default.
• W3048687053 cites W2154960154 @default.
• W3048687053 cites W2169773326 @default.
• W3048687053 cites W2248670303 @default.
• W3048687053 cites W2334454593 @default.
• W3048687053 cites W2406492757 @default.
• W3048687053 cites W2433359723 @default.
• W3048687053 cites W2483739808 @default.
• W3048687053 cites W2508085917 @default.
• W3048687053 cites W2748768370 @default.
• W3048687053 cites W2751640077 @default.
• W3048687053 cites W2766804418 @default.
• W3048687053 cites W2789052533 @default.
• W3048687053 cites W2796008823 @default.
• W3048687053 cites W2804753859 @default.
• W3048687053 cites W2811469998 @default.
• W3048687053 cites W2906571570 @default.
• W3048687053 cites W2952406328 @default.
• W3048687053 doi "https://doi.org/10.1016/j.jaad.2020.08.032" @default.
• W3048687053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32798580" @default.
• W3048687053 hasPublicationYear "2021" @default.
• W3048687053 type Work @default.
• W3048687053 sameAs 3048687053 @default.
• W3048687053 citedByCount "13" @default.
• W3048687053 countsByYear W30486870532021 @default.
• W3048687053 countsByYear W30486870532022 @default.
• W3048687053 countsByYear W30486870532023 @default.
• W3048687053 crossrefType "journal-article" @default.
• W3048687053 hasAuthorship W3048687053A5013763025 @default.
• W3048687053 hasAuthorship W3048687053A5024409404 @default.
• W3048687053 hasAuthorship W3048687053A5038975475 @default.
• W3048687053 hasAuthorship W3048687053A5039054307 @default.
• W3048687053 hasAuthorship W3048687053A5061849637 @default.
• W3048687053 hasAuthorship W3048687053A5069686473 @default.
• W3048687053 hasAuthorship W3048687053A5069977428 @default.
• W3048687053 hasBestOaLocation W30486870531 @default.
• W3048687053 hasConcept C126322002 @default.
• W3048687053 hasConcept C141071460 @default.
• W3048687053 hasConcept C156957248 @default.
• W3048687053 hasConcept C16005928 @default.
• W3048687053 hasConcept C165617652 @default.
• W3048687053 hasConcept C179755657 @default.
• W3048687053 hasConcept C2777984932 @default.
• W3048687053 hasConcept C2778975655 @default.
• W3048687053 hasConcept C2779134260 @default.
• W3048687053 hasConcept C2780132546 @default.
• W3048687053 hasConcept C2780564577 @default.
• W3048687053 hasConcept C2781059491 @default.
• W3048687053 hasConcept C44249647 @default.
• W3048687053 hasConcept C71924100 @default.
• W3048687053 hasConcept C77350462 @default.
• W3048687053 hasConceptScore W3048687053C126322002 @default.
• W3048687053 hasConceptScore W3048687053C141071460 @default.
• W3048687053 hasConceptScore W3048687053C156957248 @default.
• W3048687053 hasConceptScore W3048687053C16005928 @default.
• W3048687053 hasConceptScore W3048687053C165617652 @default.
• W3048687053 hasConceptScore W3048687053C179755657 @default.
• W3048687053 hasConceptScore W3048687053C2777984932 @default.
• W3048687053 hasConceptScore W3048687053C2778975655 @default.
• W3048687053 hasConceptScore W3048687053C2779134260 @default.
• W3048687053 hasConceptScore W3048687053C2780132546 @default.
• W3048687053 hasConceptScore W3048687053C2780564577 @default.
• W3048687053 hasConceptScore W3048687053C2781059491 @default.
• W3048687053 hasConceptScore W3048687053C44249647 @default.
• W3048687053 hasConceptScore W3048687053C71924100 @default.
• W3048687053 hasConceptScore W3048687053C77350462 @default.
• W3048687053 hasFunder F4320337415 @default.
• W3048687053 hasIssue "1" @default.
• W3048687053 hasLocation W30486870531 @default.
• W3048687053 hasOpenAccess W3048687053 @default.

• next